Merck KGaA (MKKGY) on Thursday reported higher profit for the third quarter, supported by organic growth across all three business sectors — Life Science, Healthcare, and Electronics.
Net profit increased to €898 million or €2.07 per share from €812 million or €1.86 per share in the prior year. Excluding one-time items, earnings per share pre edged up 0.9% to €2.32 from €2.30.
Operating result (EBIT) increased 11.3% to €1.221 billion from €1.097 billion last year.
EBITDA or earnings before interest, taxes, depreciation, and amortization increased 8.6% year-on-year to €1.679 billion, while EBITDA pre rose 3.1% to €1.669 billion.
Net sales grew 1% from last year to €5.318 billion, driven by a 5.2% organic increase. Sales in the Life Science segment advanced 5.9% organically to €2.241 billion, Healthcare grew 4.6% to €2.203 billion, and Electronics rose 4.8% to €875 million.
Merck confirmed and narrowed its full-year 2025 guidance, citing increased visibility as the year progresses. It now expects net sales between €20.8 billion and €21.4 billion and EBITDA pre between €6.0 billion and €6.2 billion, with the midpoint unchanged. The company forecasts earnings per share pre of around €8.20 to €8.60, organic net sales growth of about 3%, and organic EBITDA pre growth of 5%-7%.
Previously, Merck had guided for organic sales growth of 2%-5% and organic EBITDA pre growth of 4%-8%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.